Can you take Cagrilintide and Semaglutide together?

There is no specific, well-documented interaction rule for combining Cagrilintide and Semaglutide in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Cagrilintide or Semaglutide?

Cagrilintide is currently investigational (in trials) and Semaglutide is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

GLP-1 & Metabolic · Comparison

Cagrilintide vs Semaglutide

Q: What is the difference between Cagrilintide and Semaglutide?

Cagrilintide: Long-acting amylin/CGRP receptor co-agonist developed by Novo Nordisk. Reduces food intake and body weight via central satiety pathways distinct from the GLP-1 pathway. In the CagriSema combination trial with semaglutide, the combination achieved up to ~25% weight reduction — substantially greater than either agent alone. Semaglutide: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It is FDA-approved under the brand names Ozempic (diabetes) and Wegovy (weight loss) and has become one of the most widely discussed peptides in mainstream health conversations. Both are in the GLP-1 & Metabolic category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Cagrilintide

Investigational (in trials)

Long-acting amylin/CGRP receptor co-agonist developed by Novo Nordisk. Reduces food intake and body weight via central satiety pathways distinct from the GLP-1 pathway. In the CagriSema combination trial with semaglutide, the combination achieved up to ~25% weight reduction — substantially greater than either agent alone.

Full profile

Semaglutide

FDA-approved

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It is FDA-approved under the brand names Ozempic (diabetes) and Wegovy (weight loss) and has become one of the most widely discussed peptides in mainstream health conversations.

Full profile

	Cagrilintide	Semaglutide
Category	GLP-1 & Metabolic	GLP-1 & Metabolic
Also known as	AM833, amylin analogue, CagriSema partner	Ozempic, Wegovy, Rybelsus, GLP-1 agonist
Evidence	Investigational (in trials)	FDA-approved
Dosing range	0.3mg–2.4mg mg, once weekly subcutaneous	0.25mg–2.4mg mg, once weekly (injectable); once daily (oral Rybelsus)
Administration	Subcutaneous injection	Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus)
Key side effects	Nausea, Vomiting, Injection site reactions, Decreased appetite	Nausea (very common, especially during dose escalation), Vomiting, Diarrhea or constipation, Reduced appetite (intended effect)
Cited sources	2 references	4 references

Key differences

Evidence level differs: Cagrilintide is investigational (in trials), while Semaglutide is fda-approved.
Administration: Cagrilintide — Subcutaneous injection; Semaglutide — Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus).
Frequency: Cagrilintide is typically once weekly subcutaneous; Semaglutide is once weekly (injectable); once daily (oral Rybelsus).
Research depth: this profile cites 2 sources for Cagrilintide vs 4 for Semaglutide.

How each works

Cagrilintide

Cagrilintide activates amylin receptors (RAMP/CTR complexes) in the area postrema and hypothalamus, reducing food intake and slowing gastric emptying through mechanisms independent of GLP-1 signaling. This non-overlapping pathway allows combination with semaglutide without compounding GI side effects. Phase 2 CagriSema data showed 15–25% weight loss at 32 weeks, supporting the complementary mechanism hypothesis.

Semaglutide

Semaglutide has robust clinical trial data — including the STEP and SUSTAIN trial series — demonstrating significant weight loss (15–20% body weight), glycemic control, and cardiovascular risk reduction. It works by mimicking the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, and reducing appetite via central nervous system signaling.

Read the full Cagrilintide profile Read the full Semaglutide profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.